Browse News
Filter News
Found 72 articles
-
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
3/26/2024
Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”) today announced that the World Intellectual Property Organization (WIPO) has published Virios’ global patent application titled “Valacyclovir and Celecoxib for the Treatment of Alzheimer’s and COVID-19”, which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib.
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
2/29/2024
Virios Therapeutics, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2023.
-
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
2/28/2024
Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024.
-
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
1/22/2024
Virios Therapeutics, Inc. today announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”).
-
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
1/2/2024
Virios Therapeutics, Inc. today announced receipt of the Food and Drug Administration’s (“FDA”) feedback on requirements for advancing IMC-2 (combination of valacyclovir + celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC illness, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”).
-
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
11/13/2023
Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia and Long-COVID, announced financial results for the third quarter ended September 30, 2023.
-
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
11/6/2023
Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets.
-
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
10/12/2023
Virios Therapeutics, Inc. announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY.
-
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
9/18/2023
Virios Therapeutics, Inc. today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”).
-
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
9/12/2023
Virios Therapeutics, Inc. announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.
-
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8/10/2023
Virios Therapeutics, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
-
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
8/9/2023
Virios Therapeutics, Inc. today announced that the Food & Drug Administration (“FDA”) communicated that, following their initial review of the Company’s chronic toxicology program, the program’s studies appear adequate to support the safety of IMC-1 at the dose proposed by the Company for chronic use.
-
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
8/3/2023
Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report second quarter 2023 financial results on Thursday, August 10, 2023 before the open of the financial markets.
-
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
7/17/2023
Virios Therapeutics, Inc. today announced that female patients diagnosed with Long-COVID illness, otherwise known as Post-Acute Sequelae of COVID-19 infection (“PASC”), exhibited clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction and general well-being related to Long-COVID.
-
Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
5/25/2023
Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
-
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
5/15/2023
Virios Therapeutics, Inc. announced that it has submitted final toxicology reports as per Food & Drug Administration request as part of their overall review of the Company’s Phase 3 proposal.
-
Virios Therapeutics Announces First Quarter 2023 Financial Results
5/11/2023
Virios Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2023.
-
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
5/4/2023
Virios Therapeutics, Inc. today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets.
-
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
4/24/2023
Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced a program summary based on initial feedback from the U.S. Food & Drug Administration (“FDA”) on its Phase 3 FM program proposal featuring its lead development candidate IMC-1.
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
3/14/2023
Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for the fourth quarter and full year ended December 31, 2022.